Treating p53 Mutant Aggregation-Associated Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• p53 is a crucial tumor suppressor protein regulating cell growth, apoptosis, and DNA repair.
• Mutations in p53 lead to loss of function, abnormal cell proliferation, and tumor progression.
• Mutated p53 can form aggregates, resulting in a negative gain of function and promoting tumor growth.

Purpose of the Study:

• To review recent efforts in targeting p53 aggregation in cancer.
• To highlight the correlation between p53 mutant aggregation, functional loss, and tumor growth.
• To propose small stress molecules as potential therapeutic agents against p53 aggregation.

Main Methods:

• Review of recent scientific literature on p53 aggregation in cancer.
• Analysis of studies investigating the role of p53 mutant aggregates in tumor progression.
• Exploration of therapeutic strategies targeting protein aggregation diseases.

Main Results:

• p53 mutant aggregation is observed in various cancer tissues, biopsies, and in vivo studies.
• Over 50% of cancers harbor p53 mutations, with many prone to aggregation.
• Emerging therapies using polyarginine analogues and designer peptides show promise in inhibiting p53 aggregation and tumor growth.

Conclusions:

• Targeting p53 aggregation represents a novel therapeutic avenue for p53-mutant cancers.
• Small stress molecules show potential as p53-antiaggregation drugs.
• Treating cancer as a protein aggregation disease is an encouraging approach.